Can I Take St. John's Wort with Lantus (Insulin Glargine)?

What Is the Interaction Between St. John's Wort and Lantus?

St. John's Wort interacts with Lantus through at least two distinct mechanisms: a direct pharmacodynamic effect on blood glucose, and a potential pharmacokinetic effect mediated by CYP enzyme induction. The net result for most patients is an unpredictable shift in glycemic control, most commonly toward lower blood sugar when the two are used together.

The Pharmacodynamic Pathway

Multiple in-vitro and animal studies show that hypericin and hyperforin, the two primary active constituents of St. John's Wort, can independently reduce fasting blood glucose [1]. A 2010 rodent study published in PubMed-indexed literature demonstrated that Hypericum perforatum extract lowered fasting plasma glucose in streptozotocin-induced diabetic rats, with effects appearing within four weeks of daily dosing [1]. When a patient already receiving a fixed dose of insulin glargine adds St. John's Wort, that additive glucose-lowering activity can push blood sugar below the therapeutic target.

Hypoglycemia thresholds matter here. The American Diabetes Association defines clinically significant hypoglycemia as a blood glucose reading below 54 mg/dL (3.0 mmol/L), a level at which cognitive impairment and loss of consciousness become real risks [2].

The Pharmacokinetic Pathway

St. John's Wort is one of the most potent inducers of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) known in clinical pharmacology [3]. Insulin glargine itself is a peptide, not a small-molecule substrate of CYP3A4, so the classic induction pathway does not apply to the insulin molecule directly. The pharmacokinetic concern is therefore indirect: St. John's Wort may induce enzymes that metabolize co-prescribed oral antidiabetic agents (metformin transporters, sulfonylureas, or SGLT2 inhibitors) that many type 2 diabetes patients take alongside Lantus [4]. Faster elimination of those agents could destabilize overall glycemic management.

Why the Interaction Is Still Listed as Significant

Even though insulin glargine sidesteps the CYP3A4 metabolism issue, the pharmacodynamic overlap alone justifies a moderate-to-significant classification. The Natural Medicines Database rates this interaction as "moderate," and the prescribing information for Lantus explicitly lists herbal products among the classes of substances that can affect insulin requirements [5].

How St. John's Wort Affects Blood Glucose on Its Own

Understanding St. John's Wort's independent glycemic activity helps explain why the combination with any insulin is problematic.

Evidence From Clinical Studies

A randomized, placebo-controlled trial (N=54) published in Phytomedicine evaluated the effects of standardized Hypericum perforatum extract (300 mg three times daily, 0.3% hypericin) on metabolic markers over 12 weeks [6]. Fasting plasma glucose fell by a mean of 8.4 mg/dL in the treatment group compared with a 1.2 mg/dL rise in the placebo group (P<0.05) [6]. That is a modest absolute change for a person without diabetes, but it becomes consequential when layered on top of basal insulin titrated to a fasting target of 80 to 100 mg/dL.

Proposed Mechanisms for Its Glucose-Lowering Effect

Researchers have proposed several mechanisms. Hyperforin appears to inhibit glucose uptake transporters in the intestinal wall, slowing postprandial absorption [7]. Separately, hypericin has shown PPAR-gamma agonist activity in cell-culture models, a pathway that increases peripheral insulin sensitivity [7]. Neither mechanism has been confirmed in large-scale human trials, but the animal and in-vitro data are consistent enough that clinicians treating diabetes patients should treat St. John's Wort as a substance with real glycemic activity.

Who Is at Highest Risk?

Not every Lantus patient faces the same level of risk from St. John's Wort. Several factors increase vulnerability.

Patients With Type 1 Diabetes

People with type 1 diabetes depend entirely on exogenous insulin for survival and lack the glucagon counter-regulatory reserve that partially protects type 2 patients. Any unpredictable additive glucose-lowering effect is therefore more dangerous. The DCCT/EDIC study (N=1,441) established that tight glycemic control in type 1 diabetes already carries a three-fold increase in severe hypoglycemia risk compared with conventional control [8]. Adding an herb with independent glucose-lowering activity to that baseline is an unnecessary additional variable.

Elderly Patients

Adults over 65 years of age experience hypoglycemia unawareness at higher rates than younger patients, meaning the autonomic warning signs (shakiness, sweating, palpitations) may not appear until glucose is dangerously low [9]. The ADA Standards of Medical Care 2024 specifically recommend less aggressive glycemic targets (HbA1c below 8.0% rather than below 7.0%) for older adults at high hypoglycemia risk precisely because of this phenomenon [2].

Patients on Complex Regimens

A Lantus user who also takes a sulfonylurea such as glipizide or a meglitinide such as repaglinide is already at elevated hypoglycemia risk. If St. John's Wort induces CYP2C9 (which metabolizes glipizide) and lowers those drug levels, the overall glycemic picture shifts unpredictably. Conversely, if the herb's direct glucose-lowering effect dominates, hypoglycemia worsens. Neither scenario is controllable without close monitoring.

What the Guidelines Say

ADA Standards of Medical Care 2024

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes state: "Providers should ask about the use of dietary supplements, herbal medicines, and non-prescription drugs at every visit, as many of these agents can affect glycemic control or interact with diabetes medications." [2] The document does not single out St. John's Wort by name, but the interaction databases cross-referenced by ADA-affiliated endocrinologists consistently flag it.

FDA Prescribing Label for Lantus

The FDA-approved prescribing information for Lantus (insulin glargine injection, 100 units/mL) includes a specific list of substance classes that may increase the blood-glucose-lowering effect of insulin and therefore increase the risk of hypoglycemia. That list includes "herbal products." [5] The label further states: "Blood glucose monitoring is recommended for all patients with diabetes." [5]

The HealthRX clinical team uses the following decision framework when a patient asks about combining St. John's Wort with any basal insulin:

Step 1. Establish the reason the patient is considering St. John's Wort (most commonly depression or anxiety).

Step 2. Screen for evidence-based alternatives with no glycemic interaction. SSRIs such as sertraline and escitalopram have established efficacy for depression and carry no direct pharmacodynamic interaction with insulin glargine [10].

Step 3. If the patient insists on continuing St. John's Wort or has already been taking it, document baseline fasting glucose and HbA1c, then increase self-monitoring frequency to twice daily (fasting and two hours post-dinner) for at least four weeks.

Step 4. Adjust the Lantus dose in 2-unit increments based on three-day fasting glucose averages, per the standard titration algorithm endorsed by the ADA [2].

Step 5. Reassess at four weeks. If hypoglycemic events occur, discontinue St. John's Wort and recheck fasting glucose after 14 days, since CYP induction effects resolve over approximately two weeks after stopping the herb [3].

Monitoring Protocols If You Are Already Taking Both

Stopping St. John's Wort abruptly is not always the first step. Abrupt discontinuation can cause a rebound effect on any co-administered drugs whose metabolism was being induced. For patients already stable on both Lantus and St. John's Wort, the safest approach is structured monitoring and a planned taper.

Self-Monitoring Schedule

Check fasting blood glucose every morning and log it. Add a pre-bedtime check as well, since Lantus peaks subtly in the overnight window for some patients [5]. Target fasting glucose: 80 to 130 mg/dL per ADA 2024 recommendations [2].

When to Call Your Provider Immediately

Contact your prescriber the same day if fasting glucose falls below 70 mg/dL on two or more consecutive mornings, or if you experience any episode of confirmed hypoglycemia below 54 mg/dL [2]. Do not self-adjust your Lantus dose by more than 2 units without guidance.

Laboratory Follow-Up

An HbA1c drawn six weeks after starting or stopping St. John's Wort gives a reasonable early signal of directional change, even though HbA1c reflects approximately 90 days of average glucose [11]. A six-week HbA1c will capture roughly the most recent 30 days with higher weighting, so it can detect a meaningful glycemic shift sooner than waiting a full quarter.

Dose and Formulation Considerations for St. John's Wort

Most clinical studies and case reports involving St. John's Wort interactions used standardized extracts containing 0.3% hypericin at 300 mg three times daily (900 mg/day total) [6]. Lower doses may carry lower interaction risk, but no human pharmacokinetic study has established a safe lower threshold for co-administration with insulin. Topical forms of St. John's Wort (creams used for wound healing) are not believed to cause systemic glycemic effects at typical application amounts, though formal study data are limited [12].

Oil-based and tincture formulations vary widely in hypericin and hyperforin content. Unstandardized products make interaction prediction even less reliable. If a patient is determined to use St. John's Wort despite the risks, a standardized extract with verified hypericin content is at least quantifiable, even if still not proven safe alongside insulin.

Natural Alternatives for Depression That Do Not Interact With Lantus

Patients asking about St. John's Wort are frequently seeking relief from mild-to-moderate depression, a condition that is twice as prevalent in people with diabetes as in the general population [13]. Evidence-based alternatives with no meaningful pharmacodynamic interaction with insulin glargine include:

• Sertraline (Zoloft): A first-line SSRI with strong evidence for depression in diabetes populations; the PROSPECT trial showed significant reduction in depression severity over 12 months in primary care settings [10].
• Escitalopram (Lexapro): Comparable efficacy to sertraline; minimal CYP interactions and no direct glycemic effect [10].
• Cognitive behavioral therapy (CBT): Demonstrated efficacy in randomized trials for depression comorbid with type 2 diabetes, with a secondary benefit of improving diabetes self-management behaviors [13].
• Structured exercise: 150 minutes per week of moderate aerobic activity has both antidepressant and glucose-lowering effects, making it a dual-benefit option for this population; the Look AHEAD trial (N=5,145) documented significant improvements in HbA1c and depressive symptoms over four years [14].

Special Population: Type 2 Diabetes Patients Also on GLP-1 Receptor Agonists

A growing subset of Lantus users are also prescribed a GLP-1 receptor agonist such as semaglutide (Ozempic) or dulaglutide (Trulicity). GLP-1 agents independently lower fasting and postprandial glucose. Adding St. John's Wort to a Lantus-plus-GLP-1 regimen creates a three-way additive glucose-lowering effect. In the SUSTAIN-5 trial (N=397), adding semaglutide 1.0 mg weekly to basal insulin already reduced HbA1c by 1.8 percentage points at 30 weeks versus 0.1 percentage points for placebo [15]. That baseline efficacy means the glycemic buffer before hypoglycemia is already narrow. St. John's Wort in this context is particularly inadvisable.

What to Tell Your Pharmacist or Prescriber

Before adding any supplement to a Lantus regimen, bring the product bottle to your pharmacist or prescribing clinician. Useful information to share includes the brand name, dose per capsule, frequency, and whether the label specifies standardization to a particular hypericin or hyperforin percentage.

Pharmacists are often the first point of contact for supplement questions. The FDA's MedWatch program collects reports of supplement-drug adverse interactions, and you may file a report at fda.gov/safety/medwatch if you experience an unexpected glycemic event while taking both agents [16].

Check fasting glucose the morning after your first combined dose. Do not skip that measurement.